Vera Krymskaya

Has grant

Professor

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)

Open Date: 2019-01-01

Close Date: 2023-12-31

Grant: Close

Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)

Open Date: 2016-04-01

Close Date: 2020-03-31

Grant: Close

Role of folliculin (FLCN) in lung cell survival

Open Date: 2012-05-01

Close Date: 2017-02-28

Grant: Close

TSC signaling and pulmonary LAM

Open Date: 2012-05-01

Close Date: 2017-02-28

Grant: Close

The Role of TSC2 and Rho GTPases in LAM

Open Date: 2008-07-10

Close Date: 2014-06-30

Articles (7)

Year:

2026

Year:

2025

Lymphangioleiomyomatosis (LAM) is a rare disease of women in which TSC2 deficient ‘LAM cells’ with dysregulated mTOR signalling and recruited fibroblasts form nodules causing lung cysts and respiratory failure. We examine if mTOR dysregulation can induce senescence and impair the response to lung injury in LAM. The senescence markers p21, p16 and the SenMayo gene set are increased in LAM lungs and colocalise with alveolar type 2 cells. LAM models induce mTOR dependent senescence in alveolar type 2 cell organoids in vitro and in vivo. IL-6 produced by LAM cells, induces p16 and p21 in alveolar type 2 cells, inhibits epithelial wound resolution and is related to lung function in LAM patients. Rapamycin and the IL-6 receptor antagonist Tocilizumab reduce alveolar type 2 cell organoid p21 accumulation and Tocilizumab enhances epithelial wound repair. Targeting IL-6 signalling in parallel with mTOR inhibition, may reduce lung damage in LAM.

Year:

2025

Lymphangioleiomyomatosis (LAM) is a rare genetic lung disease. Unfortunately, treatment with the mTORC1 inhibitor Rapamycin only slows disease progression, and incomplete responses are common. Thus, there remains an urgent need to identify new targets for the development of curative LAM treatments. Nitazoxanide (NTZ) is an orally bioavailable antiprotozoal small molecule drug approved for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in children and adults, with a demonstrated mTORC1 inhibitory effect in several human cell lines. NTZ’s excellent safety profile characterized by its more than 20 years of clinical use makes it a promising candidate for repurposing. Our rationale for this study was to further investigate NTZ’s effect using in vitro and in vivo LAM models and to elucidate the underlying molecular mechanism beyond mTORC1 inhibition. For this purpose, we investigated cell proliferation, cell viability, and changes in protein phosphorylation and expression in primary human cell cultures derived from LAM lung samples before translating our results into a syngeneic mouse model utilizing Tsc2-null cells. NTZ reduced cell growth for all tested cell lines at a dose of about 30 µM. Lower doses than that had no effect on cell viability, but doses above 45 µM lowered the viability by about 10 to 15% compared to control. Interestingly, our western blot revealed no inhibition of mTORC1 and only a mild effect on active ß-Catenin. Instead, NTZ had a pronounced effect on reducing pAkt. In the mouse model, prophylactic NTZ treatment via the intraperitoneal and oral routes had some effects on reducing lung lesions and improving body weight retention, but the results remain inconclusive.

Year:

2024

Recurrent infections are a hallmark of STAT3 dominant-negative hyper-IgE syndrome (STAT3 HIES), a rare immunodeficiency syndrome previously known as Jobs syndrome, along with elevated IgE levels and impaired neutrophil function. We have been developing nanoparticles with neutrophil trophism that home to the sites of infection via these first-responder leukocytes, named neutrophil-avid nanocarriers (NANs). Here, we demonstrate that human neutrophils can phagocytose nanogels (NGs), a type of NAN, with enhanced uptake after particle serum opsonization, comparing neutrophils from healthy individuals to those with STAT3 HIES, where both groups exhibit NG uptake; however, the patient group showed reduced phagocytosis efficiency with serum-opsonized NANs. Proteomic analysis of NG protein corona revealed complement components, particularly C3, as predominant in both groups. Difference between groups includes STAT3 HIES samples with higher neutrophil protein and lower acute-phase protein expression. The study suggests that despite neutrophil dysfunction in STAT3 HIES, NANs have potential for directed delivery of cargo therapeutics to improve neutrophil infection clearance.

Year:

2024

Year:

2021

Year:

2020

Collaborators (8)

Kyungtae Lim

Assistant Professor

Korea University

SOUTH KOREA
View details

Y S Prakash

Professor of Anesthesiology and Physiology

Mayo Clinic

UNITED STATES
View details

Simon Johnson

Director

Nottingham University Hospitals NHS Trust

UNITED KINGDOM
View details

Darrell Kotton

boston university chobanian and avedisian school of medicine

UNITED STATES
View details

Rachel Chambers

University College London

UNITED KINGDOM
View details

Elizabeth Redente

Professor

National Jewish Health

UNITED STATES
View details

MeiLan Han

Professor

University of Michigan

UNITED STATES
View details

Hrishikesh S. Kulkarni

Washington University School of Medicine

UNITED STATES
View details